-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca: Positive TEZSPIRE results from the eosinophilic esophagitis phase III CROSSING trial were announced at the European Joint Gastroenterology Week, including symptom improvement, histology, and endoscopic remission.

Zhitongcaijing·10/20/2026 13:09:28
Listen to the news
AstraZeneca: Positive TEZSPIRE results from the eosinophilic esophagitis phase III CROSSING trial were announced at the European Joint Gastroenterology Week, including symptom improvement, histology, and endoscopic remission.